debate: optimal approach for the management of cll patients with del(17p) - novel agents
Published 8 years ago • 289 plays • Length 13:55Download video MP4
Download video MP3
Similar videos
-
15:23
debate: optimal approach for the management of cll patients with del(17p) - ibrutinib
-
14:21
debate: which is the optimal approach for cll? - fcr
-
21:05
cll: optimal approaches for patients with deletion 17p
-
19:14
debate: best approach for multiple relapsed cll after chemoimmunotherapy - other novel agents
-
15:02
debate: will novel-agent based combination therapy become standard of care for cll? - no
-
12:08
debate: which is the optimal approach for cll? - br
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
14:13
debate: do we have enough data to eliminate chemotherapy from initial treatment for cll? - yes
-
13:57
speech on prisons education and employment strategy | rory stewart mp
-
1:00:00
iq2 debate: prisons work
-
13:19
ighv and tp53 sequencing: clinical utility in chronic lymphocytic leukemia (cll)
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
24:17
combination of novel agents in cll: is this the final answer?
-
11:23
debate: best approach for multiple relapsed cll after chemoimmunotherapy - kinase inhibitor
-
14:07
novel agents in the pipeline for cll & lymphoma
-
22:08
role of chemotherapy in cll management
-
27:18
novel treatment options in cll
-
16:39
fcr and br: when to use, how to use?
-
12:34
debate: is it appropriate to treat patients with cll earlier in the era of novel agents? - no
-
22:47
the sequencing of novel agents: does it matter?
-
20:21
novel agents in elderly cll patients: should the approach be different?